Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Jun 26, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a medication called dupilumab to see if it can help people with Hypereosinophilic Syndrome (HES) who are not fully responding to their current treatments. HES is a condition where the body has too many eosinophils, a type of white blood cell, which can lead to damage in various organs like the lungs, skin, and intestines. The trial is looking for adults aged 18 and older who have been on certain eosinophil-lowering treatments for at least six months but still have bothersome symptoms. Participants will receive dupilumab injections every one or two weeks for 24 weeks, and if it helps, they may continue for another 24 weeks.

Throughout the study, participants will have several clinic visits where they will undergo tests, including blood tests and assessments of how HES impacts their daily life. It's important for potential participants to know that they should not be pregnant, should not have certain health conditions, and must be willing to follow specific guidelines regarding contraception and participation. The trial aims to gather information on the effectiveness and safety of adding dupilumab to existing therapies for HES, helping researchers find better treatment options for this challenging condition.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• To be eligible to participate in this study, an individual must meet all the following criteria:
• • 1. Age \>=18 years
• • 2. Documented diagnosis of HES with historic AEC\>1.5x10\^9/L on two occasions, no secondary etiology for the eosinophilia despite careful clinical evaluation, and evidence of end organ damage (histologic evidence of tissue infiltration by eosinophils and/or objective evidence of clinical pathology in any organ system that is temporally associated with eosinophilia and not clearly attributable to another cause)
• • 3. Currently receiving treatment with an eosinophil-lowering biologic (mepolizumab, reslizumab, or benralizumab) for a minimum of 24 weeks
• • 4. AEC\<0.5x10\^9/L
• 5. Residual symptoms after a minimum of 24 weeks of eosinophil-lowering biologic therapy with at least 1 most bothersome symptom of moderate severity (HES-SI score \>=2) consistent with \>=1 of the following diagnoses:
• • a. asthma, defined as physician-documented asthma requiring medium to high dose inhaled corticosteroids + long-acting beta agonist b. atopic dermatitis, defined as physician-documented chronic or recurrent inflammatory skin disease
• • c. CRSwNP, defined as evidence of rhinosinusitis and nasal polyposis on physical examination or imaging
• • d. EoE, defined as biopsy-proven esophageal eosinophilia \>15 eosinophils/high power field
• • 6. For participants who can become pregnant: sexual abstinence or use of highly effective contraception (i.e., partner vasectomy, bilateral tubal ligation, IUD, progestin implants, and other hormonal methods) starting 4 weeks prior to study drug initiation and agreement to use such a method during study participation and for an additional 12 weeks after the end of study drug administration
• • 7. Participation in NIH protocol 94-I-0079 (Activation and function of eosinophils in conditions with blood or tissue eosinophilia)
• • 8. Ability of subject to understand and the willingness to sign a written informed consent document
• EXCLUSION CRITERIA:
• An individual who meets any of the following criteria will be excluded from participation in this study:
• • 1. Pregnancy or lactation
• • 2. Known allergic reaction to dupilumab or any of the excipients in Dupixent(TM)
• • 3. Febrile illness within 7 days of enrollment
• • 4. Treatment with an investigational drug or other intervention other than mepolizumab, reslizumab, or benralizumab within 12 weeks or 4 half-lives of the investigational agent (whichever is longer).
• • 5. Known or suspected acquired or inborn immunodeficiency disorder, including HIV infection
• • 6. Known diagnosis of eosinophilic granulomatosis with polyangiitis
• • 7. Change in eosinophil-active therapy within the past 6 weeks, including but not limited to topical corticosteroids, leukotriene inhibitors, initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food (in patients with gastrointestinal involvement), and proton pump inhibitors (in patients with gastrointestinal involvement)
• • 8. Planned or anticipated major surgical procedure during the study
• • 9. Active parasitic infection
• • 10. History of malignancy within 5 years, excluding completely treated in situ carcinoma of the cervix, or squamous or basal cell carcinoma of the skin
• • 11. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study
• For patients with eosinophilic gastrointestinal disease only:
• • 1. Active infection with Helicobacter pylori
• • 2. History of achalasia, Crohn s disease, ulcerative colitis, celiac disease, or prior esophageal surgery
• • 3. Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to 10 mm upper endoscope